4-Methyl-α-methyltryptamine

4-Methyl-α-methyltryptamine
Clinical data
Other names4-Me-αMT; 4-Me-AMT; 4-Methyl-αMT; 4-Methyl-AMT; 4,α-Dimethyltryptamine; 4,α-DMT; MP-809; MP809; Methyl-2-methyltryptamine
Routes of
administration
Oral
Drug classAntidepressant
ATC code
  • None
Legal status
Legal status
Identifiers
  • 1-methyl-2-(4-methyl-1H-indol-3-yl)-ethylamine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC12H16N2
Molar mass188.274 g·mol−1
3D model (JSmol)
  • CC(N)Cc2c1c([nH]c2)cccc1C
  • InChI=1S/C12H16N2/c1-8-4-3-5-11-12(8)10(7-14-11)6-9(2)13/h3-5,7,9,14H,6,13H2,1-2H3 Y
  • Key:KEOYEGHPRBDSKD-UHFFFAOYSA-N Y
  (verify)

4-Methyl-α-methyltryptamine (4-Me-αMT or 4-Me-AMT), also known as 4,α-dimethyltryptamine (4,α-DMT) and by its developmental code name MP-809, is an experimental antidepressant of the tryptamine and α-alkyltryptamine families. It is closely structurally related to serotonergic psychedelics and entactogens like α-methyltryptamine (αMT) and α-ethyltryptamine (αET). 4-Me-αMT was investigated as an antidepressant by Sandoz in Canada in the early 1960s, although it was never marketed.